Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 38.3% in August

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 148,118 shares, a decrease of 38.3% from the July 30th total of 240,225 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 159,888 shares, the days-to-cover ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

Several research firms have commented on DSNKY. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Down 0.2%

DSNKY opened at $18.02 on Wednesday. Daiichi Sankyo has a 12 month low of $14.98 and a 12 month high of $27.50. The company has a current ratio of 2.92, a quick ratio of 1.64 and a debt-to-equity ratio of 0.29. The business’s 50-day moving average price is $17.13 and its 200-day moving average price is $17.34. The company has a market cap of $33.57 billion, a P/E ratio of 20.95, a P/E/G ratio of 2.48 and a beta of -0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, equities analysts expect that Daiichi Sankyo will post 0.97 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.